About the Company
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ATRA News
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023
ATRA stock results show that Atara Biotherapeutics missed analyst estimates for earnings per share and missed on revenue for ...
Atara Biotherapeutics: Q4 Earnings Snapshot
THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Thursday reported a loss of $60.5 million in its fourth quarter. The Thousand Oaks, California-based ...
Analysts Say You Should Hold Your Position In Atara Biotherapeutics Inc (NASDAQ: ATRA)
Atara Biotherapeutics Inc (NASDAQ:ATRA) traded at $0.60 at close of the session on Monday, March 18, made a downward move of -4.06% on its previous day’s price.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU) and Neurogene (NGNE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fusion Pharmaceuticals (FUSN – Research ...
Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
The price trend for Arcutis Biotherapeutics, Inc. (ARQT) has been bearish lately and the stock has lost 6.5% over the past two weeks. However, the formation of a hammer chart pattern in its last ...
Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)
Burns covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, Atara Biotherapeutics ... Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. I-MAB has an analyst ...
Stock Indexes Consolidate Below Thursday’s Record Highs
The S&P 500 Index ( $SPX) ( SPY) this morning is down -0.11%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is down -0.14%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is down -0.25%.
Stocks Consolidate Below This Week’s Record Highs
FedEx ( FDX) is up more than +7% to lead gainers in the S&P 500 after reporting Q3 adjusted EPS of $3.86, stronger than the consensus of $3.46 billion, and announcing a $5 billion stock buyback plan.
Atara Biotherapeutics: Q4 Earnings Insights
Atara Biotherapeutics ATRA reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM. Here's what investors need to know about the announcement. Atara Biotherapeutics missed estimated ...
Loading the latest forecasts...